Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis

Company Overview

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Key Stats

• Today's Range: $0.0111 to $0.0111
• 50-Day Range: $0.01 to $0.44
• 52-Week Range: $0.01 to $26.25
• Volume: 1,128 shs
• Average Volume: 165,918 shs
• Market Capitalization: $13.79 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Virpax Pharmaceuticals Stock Analysis - MarketRank™

Virpax Pharmaceuticals scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Virpax Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Virpax Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.96% of the outstanding shares of Virpax Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Virpax Pharmaceuticals has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Virpax Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Virpax Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.96% of the outstanding shares of Virpax Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Virpax Pharmaceuticals has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Virpax Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Virpax Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Virpax Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 32.23% of the stock of Virpax Pharmaceuticals is held by institutions.

VRPX Stock Analysis - Frequently Asked Questions

How have VRPX shares performed this year?

Virpax Pharmaceuticals' stock was trading at $9.4975 at the beginning of the year. Since then, VRPX shares have decreased by 99.9% and is now trading at $0.0111.

When did Virpax Pharmaceuticals' stock split?

Virpax Pharmaceuticals's stock reverse split on Friday, March 1st 2024.The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Virpax Pharmaceuticals IPO?

Virpax Pharmaceuticals (VRPX) raised $15 million in an IPO on Wednesday, February 17th 2021. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

How do I buy shares of Virpax Pharmaceuticals?

Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Virpax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Virpax Pharmaceuticals investors own include AMC Entertainment (AMC), Dare Bioscience (DARE), Rallybio (RLYB), Plug Power (PLUG), SNDL (SNDL) and SOS (SOS).

Company Calendar

• Today: 9/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VRPX
• CIK: 1708331
• Web: www.virpaxpharma.com
• Phone: 610-727-4597
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,554.34%
• Return on Assets: -338.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.13
• Quick Ratio: 0.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.65 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 1,242,000
• Free Float: 4,707,000
• Market Cap: $13.79 thousand
• Optionable: Not Optionable
• Beta: 1.49